Synlogic Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synlogic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Synlogic saw a increase in short interest in February. As of February 12th, there was short interest totaling 457,600 shares, an increase of 36.8% from the January 28th total of 334,500 shares. Based on an average daily volume of 1,910,000 shares, the short-interest ratio is presently 0.2 days. Currently, 2.2% of the company's shares are short sold.
View Synlogic's Short Interest.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Synlogic.

Synlogic, Inc. (NASDAQ:SYBX) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.11. Synlogic had a negative net margin of 2,761.83% and a negative trailing twelve-month return on equity of 41.64%.
View Synlogic's earnings history.

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SYBX shares have increased by 146.8% and is now trading at $3.80.
View which stocks have been most impacted by COVID-19.

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

3 Wall Street analysts have issued 12-month price objectives for Synlogic's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Synlogic's stock price to reach $11.50 in the next year. This suggests a possible upside of 202.6% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Some companies that are related to Synlogic include Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Affimed (AFMD), BeyondSpring (BYSI), Neoleukin Therapeutics (NLTX), Crinetics Pharmaceuticals (CRNX), Amryt Pharma (AMYT), Spero Therapeutics (SPRO), Homology Medicines (FIXX), Athenex (ATNX), SIGA Technologies (SIGA), Spruce Biosciences (SPRB), Marinus Pharmaceuticals (MRNS), 89bio (ETNB) and Wave Life Sciences (WVE).
View all of SYBX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.82%), BlackRock Inc. (1.18%), Renaissance Technologies LLC (1.00%), Verition Fund Management LLC (0.07%), Jane Street Group LLC (0.05%) and Flagship Harbor Advisors LLC (0.05%).
View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., and Jane Street Group LLC.
View insider buying and selling activity for Synlogic or view top insider-selling stocks.

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Monticello Wealth Management LLC, Flagship Harbor Advisors LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Synlogic or or view top insider-buying stocks.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $3.80.

Synlogic has a market capitalization of $132.37 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

Synlogic employs 76 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]